Abcam Signs License Agreement with Pfizer
News Jun 12, 2013
Abcam Plc. has announced that it has entered into a license agreement with Pfizer. Under the terms of the agreement, Abcam’s Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.
The agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research.
The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.
Steve Roome, General Manager of Abcam Biochemicals, commented: “We are delighted to have signed the license agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.